Cansino announced that the company recently received the “Drug Clinical Trial Approval Notice” for the 24-valent pneumococcal polysaccharide conjugate vaccine approved and issued by the State Drug Administration. The vaccine uses a covalent combination of polysaccharide antigen with a protein carrier and dual carrier technology. It is intended for vaccination of people aged 2 months and above to prevent infectious diseases caused by 24 pneumococcal serotypes. Vaccine development is difficult and the cycle is long. Before marketing and sale, it is necessary to apply for clinical trials, conduct clinical trials, apply for drug registration and marketing permits, and batch issuance of products.

Cansino announced that the company recently received the “Drug Clinical Trial Approval Notice” for the 24-valent pneumococcal polysaccharide conjugate vaccine approved and issued by the State Drug Administration. The vaccine uses a covalent combination of polysaccharide antigen with a protein carrier and dual carrier technology. It is intended for vaccination of people aged 2 months and above to prevent infectious diseases caused by 24 pneumococcal serotypes. Vaccine development is difficult and the cycle is long. Before marketing and sale, it is necessary to apply for clinical trials, conduct clinical trials, apply for drug registration and marketing permits, and batch issuance of products.